



HHS Public Access

Author manuscript

Circ Res. Author manuscript; available in PMC 2016 March 27.

Published in final edited form as:

Circ Res. 2015 March 27; 116(7): 1231–1244. doi:10.1161/CIRCRESAHA.116.302855.

Endothelial cell metabolism in normal and diseased vasculature

Guy Eelen^{1,2}, Pauline de Zeeuw^{1,2}, Michael Simons^{3,4}, and Peter Carmeliet^{1,2}

¹Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, Department of Oncology, University of Leuven, Leuven, B-3000, Belgium

²Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, Leuven, B-3000, Belgium

³Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, New Haven, CT 06520, USA

⁴Department of Cell Biology, Yale University School of Medicine, New Haven, CT 06520, USA

Abstract

Higher organisms rely on a closed cardiovascular circulatory system with blood vessels supplying vital nutrients and oxygen to distant tissues. Not surprisingly, vascular pathologies rank among the most life-threatening diseases. At the crux of most of these vascular pathologies are (dysfunctional) endothelial cells (ECs), the cells lining the blood vessel lumen. ECs display the remarkable capability to switch rapidly from a quiescent state to a highly migratory and proliferative state during vessel sprouting. This angiogenic switch has long been considered to be dictated by angiogenic growth factors (*eg* vascular endothelial growth factor; VEGF) and other signals (*eg* Notch) alone, but recent findings show that it is also driven by a metabolic switch in ECs. Furthermore, these changes in metabolism may even override signals inducing vessel sprouting. Here, we review how EC metabolism differs between the normal and dysfunctional/diseased vasculature and how it relates to or impacts the metabolism of other cell types contributing to the pathology. We focus on the biology of ECs in tumor blood vessel and diabetic ECs in atherosclerosis as examples of the role of endothelial metabolism in key pathological processes. Finally, current as well as unexplored 'EC metabolism'-centric therapeutic avenues are discussed.

Keywords

endothelial cell metabolism; angiogenesis; diabetes; atherosclerosis; cancer

Editorial correspondence: P. Carmeliet, M.D., Ph.D., Laboratory of Angiogenesis & Neurovascular link, Vesalius Research Center, VIB, KULeuven, Campus Gasthuisberg, Herestraat 49, B-3000, Leuven, Belgium, tel: 32-16-34.57.72; fax: 32-16-34.59.90, peter.carmeliet@vib-kuleuven.be.

In January 2015, the average time from submission to first decision for all original research papers submitted to *Circulation Research* was 14.7 days.

Disclosures

P.C. declares to be named as inventor on patent applications claiming subject matter related to the findings reviewed in this publication.

Angiogenesis and endothelial cell biology in a nutshell

Blood vessels supply tissues with oxygen and nutrients, whereas lymphatic vessels absorb and filter interstitial fluids from these tissues^{1,2}. While mostly remaining quiescent throughout adult life, blood vessels maintain the capacity to rapidly form new vasculature in response to injury or in pathological conditions. Key players in this new vessel formation are the blood vessel lining endothelial cells (ECs). Capillary sprouting, an important component of neovascularization, is accomplished by interactions among three different EC subtypes, each carrying out highly specific roles during this process³: *tip cells* are highly migratory, non-proliferative ECs that guide and pull the new sprout in the correct direction, *stalk cells* elongate the new sprout by their high proliferative capacity, and quiescent *phalanx cells* mark the more mature part of the vessel by their typical cobblestone shape⁴.

The specification of ECs into one of these subtypes is mainly driven by the key angiogenic *vascular endothelial growth factor* (VEGF) and occurs upon VEGF production by hypoxic tissues and macrophages trying to regain oxygenation and nutrient supply by attracting new vessel sprouts. These processes have been best studied in retinal angiogenesis where a continuous VEGF gradient will eventually reach the existing vascular front allowing VEGF to bind the VEGF receptor 2 (VEGFR2) in ECs, predestining these ECs to become tip cells. Intriguingly, the newly appointed tip cells themselves instruct their neighboring ECs to adopt a stalk cell phenotype: the Notch ligand Delta like 4 (Dll4) produced by tip cells binds Notch receptors in adjacent ECs whereby the Notch intracellular domain (NICD) is released and reprograms the cell to express the decoy receptor VEGFR1 at the expense of VEGFR2, causing reduced VEGF sensitivity and enforcing stalk cell behavior⁵. Although seemingly rigid, tip/stalk specification is a highly dynamic feature in which, through continuous cell shuffling, the EC with the highest VEGFR2 / VEGFR1 expression ratio (and thus the highest VEGF responsiveness) is at the tip of the new sprout at every given moment⁶.

When the tip cell encounters another tip cell or a pre-existing vessel, both will fuse to form a lumenized, perfused vessel, a process referred to as anastomosis. As the new vessel sprout matures, ECs adopt a more quiescent, non-proliferative and non-migratory, cobblestone-like phenotype called phalanx cells. High VEGFR1 levels and subsequent low VEGF responsiveness enable these cells to stay quiescent for years. By virtue of their tight monolayer organization and barrier function, phalanx cells facilitate blood flow within the blood vessel lumen, which further promotes quiescence of phalanx cells³. In addition, ECs in the maturing vessel excrete platelet derived growth factor B (PDGF-B) to attract PDGF receptor β (PDGF-R β) expressing pericytes. Coverage of the nascent vessel with these mural cells contributes to proper vessel functioning and stability⁷.

EC metabolism in health: driving vessel sprouting

Although often mistakenly considered as inert lining material with the sole function of guiding and conducting blood, ECs are key players in health as well as in life-threatening vascular diseases. Before discussing the metabolism of ECs and other cell types involved in vascular pathologies, we will briefly review glucose, fatty acid and amino acid metabolism, the three major energy and biomass generating metabolic pathways in healthy ECs (Fig. 1),

and highlight their importance in normal vessel sprouting. Most of the findings reported below are from *in vitro* experiments and, although they have tremendously increased our understanding of EC metabolism, await further confirmation in an *in vivo* setting.

ATP generation through oxidative phosphorylation (OXPHOS) could be expected to be the preferred energy-yielding pathway in ECs based on their immediate exposure to blood stream oxygen. However, ECs have a relatively low mitochondrial content⁸ and rely primarily on glycolysis with *in vitro* glycolysis rates comparable to or even higher than in cancer cells and exceeding glucose oxidation and fatty acid oxidation flux by over 200-fold^{9–11}. Per molecule of glucose, ECs miss out on approximately 34 molecules of ATP by opting for glycolysis instead of oxidative phosphorylation. Notwithstanding the lower ATP per glucose yield, high glycolytic flux can yield more ATP in a shorter time than OXPHOS when available glucose is unlimited, and has the advantage of shunting glucose into glycolysis side-branches (see below) for macromolecule synthesis. Whether large amounts of glucose are indeed available in the metabolically harsh environment into which vessels sprout, remains to be determined. Additional advantages of ‘aerobic glycolysis’ in ECs could be 1) lower OXPHOS-generated reactive oxygen species (ROS) levels, 2) preservation of maximal amounts of oxygen for transfer to perivascular cells, 3) adaptation of ECs to the hypoxic surroundings they will grow into, and 4) production of lactate as a pro-angiogenic signaling molecule¹².

Upon VEGF-stimulation, ECs double their glycolytic flux to meet increased overall energy and biomass demands and to locally supply energy for cytoskeleton remodeling during EC migration. As such, ECs display increased expression of the glycolysis activator 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3)¹⁰, which by virtue of its much higher kinase activity (as compared to its phosphatase activity) produces large amounts of fructose-2,6-bisphosphate (F2,6P₂) to activate phosphofructokinase-1 (PFK1), a rate-limiting enzyme in glycolysis. Interestingly, both genetic and pharmacologic inhibition of PFKFB3 results in decreased sprouting capacity in *in vitro* spheroid assays and in reduced vessel branching and outgrowth *in vivo*, even though there is only a partial reduction in glycolytic flux (~ 60% of total flux is retained)^{10, 13}. Moreover, *in vitro* knock-down of PFKFB3 diminished tip cell behavior even when Notch was simultaneously knocked-down to create a strong genetic ‘pro-tip cell’ cue. Conversely, PFKFB3 overexpression was able to push ECs that were genetically instructed to become stalk cells by NICD overexpression, back into a tip cell phenotype, underscoring the pivotal role of glycolysis in ECs¹⁰. As mentioned above, blood flow contributes to phalanx cell quiescence. Remarkably, the laminar shear stress exerted by blood flow reduced glucose uptake, glycolysis and mitochondrial content in ECs and lowered the expression of PFKFB3 and PFK1 to sustain a metabolically quiescent behavior. Mechanistically, the flow-responsive Krüppel-like factor 2 (KLF2) transcription factor was found to bind to a KLF2 binding site in the PFKFB3 promoter to subsequently repress PFKFB3 transcription¹⁴. Taken together these findings underscore the pivotal role of glycolysis in EC subtype specification.

Glucose can also be shunted into two *side branches of glycolysis*: the hexosamine biosynthesis pathway (HBP) and the pentose phosphate pathway (PPP). The HBP generates *N*-acetylglucosamine for protein *O*- and *N*-glycosylation and uses glucose, glutamine,

acetyl-CoA and uridine for that purpose¹⁵. In ECs, the functionality of key angiogenic proteins like Notch and VEGFR2 depends on their glycosylation status^{16, 17}. Although its *in vivo* role is less well characterized, the endothelial HBP possibly serves as a nutrient-sensing pathway to guide new vessels to nutrient-rich regions by glycosylating these key angiogenic proteins. Inhibition of the HBP significantly reduces angiogenesis¹⁸.

Glucose enters the PPP as glucose-6-phosphate (G6P) to fuel 5-carbon sugar (pentose) production for nucleotide and nucleic acid synthesis¹⁹. Genetic or pharmacologic inhibition of G6P dehydrogenase (G6PDH), the rate-limiting enzyme of the oxidative PPP branch (oxPPP; generating nicotinamide adenine dinucleotide phosphate (NADPH) and ribulose-5-phosphate (Ru5P)), and transketolase, a rate-limiting enzyme in the non-oxidative PPP branch (non-oxPPP, yielding ribose-5-phosphate (R5P)) reduces EC viability and migration^{20, 21}. The oxPPP generates NADPH that can be used as reducing equivalent in lipid synthesis and in restoring the antioxidant capacity of glutathione by converting the oxidized form (GSSG) back to the reduced form (GSH)¹⁹.

Besides glucose, *fatty acids* represent another fuel source for ECs. *In vitro* glucose deprivation, for example, causes ECs to increase their *fatty acid* oxidation (FAO) flux in an AMP-activated protein kinase (AMPK)-dependent manner⁹. Interestingly, VEGF enhances the expression of the fatty acid uptake and trafficking protein FABP4, which is required for normal EC proliferation²². Given its presumably modest contribution to total ATP levels in ECs¹⁰, the exact role of FAO is uncertain at present. Whether FAO is involved in EC redox homeostasis (as is the case in stressed cancer cells^{23, 24}) and biosynthesis of macromolecules, remains to be determined. Interestingly, capillary ECs in fatty acid consuming tissues (such as the heart and skeletal muscle) express FABP4 and FABP5 to transport fatty acids across the endothelium into these tissues²⁵ (a process requiring tight control given that excess fatty acid uptake by the tissue can cause insulin resistance). Transendothelial transport of lipids is regulated by VEGF-B, though this matter is debated^{26, 27}. The required fatty acids are supplied inside the capillary lumen through hydrolysis of triglyceride-rich lipoproteins by lipoprotein lipase (LPL). Intriguingly, LPL is secreted into the interstitium by parenchymal cells and relies on the glycosylphosphatidylinositol-anchored high-density-lipoprotein-binding protein 1, expressed by the capillary ECs, to be transported to the capillary lumen²⁸.

Although gaining increasing attention in cancer cells, *amino acid (AA) metabolism* is largely understudied in ECs. Arginine is the exception to this rule and has been broadly studied for its conversion to citrulline and nitric oxide (NO), an important regulator of EC function, by endothelial nitric oxide synthase (eNOS)²⁹. The non-essential amino acid glutamine is the most abundant amino acid in the plasma, which makes it a supposedly easily accessible fuel. Glutamine has the added value to contribute both its carbons and nitrogens to ECs' metabolism (though the relative importance of both in vessel sprouting remains to be determined) and can therefore serve different, mostly biosynthetic metabolic fates³⁰. ECs express the solute carrier family 1 member 5 (SLC1A5) to take up glutamine and were reported to have high glutaminase (GLS) activity^{31, 32}; this enzyme converts glutamine to glutamate in the first and rate-limiting step of glutaminolysis (the series of reactions that serves to supply glutamine carbons to the tricarboxylic acid (TCA) to replenish

intermediates that were used for biosynthesis purposes (anaplerosis)) (Fig. 1). Inhibition of glutaminase causes ECs to senesce prematurely and to stop proliferating³³. Two different GLS isozymes have been identified in mammalian cells; kidney-type GLS1 and liver-type GLS2. In cancer cells at least, these isozymes serve different functions: GLS1 is a *c-MYC* target and mainly drives glutamine carbons into the TCA^{34,35}, whereas GLS2 is downstream of p53 and preferably shunts glutamine carbons and nitrogen into glutathione for antioxidant purposes³⁶. Remarkably, transcriptomic analysis of laser capture micro-dissected tip cells from the microvasculature in mouse postnatal retinas, showed increased expression of GLS2³⁷; the exact biological significance hereof is unknown at present. Glutamine-derived glutamate can be used for the production of other non-essential amino acids. Serine is of particular interest here since its synthesis requires the α -nitrogen from glutamate and 3-phosphoglycerate (3PG) from the glycolytic pathway and thus exemplifies the functional interconnection between glucose and glutamine metabolism³⁸ (Fig. 1). ECs express D-3-phosphoglycerate-dehydrogenase, the rate-limiting enzyme in serine synthesis. Serine seems to predominantly affect blood pressure by promoting vasodilation through activation of K_{Ca} channels present in the endothelium^{39,40}. Furthermore, by virtue of its interconversion with glycine, serine can feed one-carbon metabolism, which is crucial for redox balance and for nucleotide, protein and lipid synthesis⁴¹.

The above metabolic pathways in ECs (and the rate-limiting enzymes therein) are not only controlled by substrate and end product availability but also by key metabolic ‘sensors’ like the highly conserved serine threonine kinase adenosine monophosphate (AMP)-activated protein kinase (AMPK). Unmet energy demands, reflected by increased intracellular AMP levels cause AMPK to increase flux through energy generating metabolic pathways (*eg* FAO) to maintain cellular energy levels. Specifically in ECs, AMPK can also be activated by EC-specific stimuli such as hypoxia/ischemia and (blood flow) shear stress. For more details on the role of endothelial AMPK in angiogenesis and ischemia as well as on the link with nitric oxide (NO) and statins (see below) the reader is referred to the following reviews^{42,43}. For additional information on how signaling proteins drive cellular metabolism (not restricted to ECs), the reader is referred to the following reviews^{44–46}.

The endothelium is one of the largest organs in the body and probably also one of the most heterogeneous. The endothelium comprises of not just one stereotype EC but rather a large collection of EC subtypes differing in phenotype, function and location. Exactly how this heterogeneity translates to EC metabolism – or *vice versa* how EC metabolism drives this heterogeneity – remains largely unknown. Probably if not certainly, the different EC types adapt the flux through the metabolic pathways generalized above in order to meet their highly specific energy, redox and biosynthesis demands. Arterial, venous, microvascular and lymphatic ECs each have different functions and face different oxygen levels, most probably reflected by differences in their core metabolism. As such, pulmonary microvascular ECs differ from pulmonary arterial ECs in glucose and oxygen consumption and in total intracellular ATP levels⁴⁷. Brain microvascular ECs have significantly more mitochondria than peripheral ECs⁴⁸; whether this implies increased oxidative metabolism in these cells remains unknown. EC heterogeneity and possible metabolic consequences also apply to the disease state (see below). Tumor ECs for example differ significantly when isolated from

high- *versus* low-metastatic tumors ⁴⁹ (tumor endothelium heterogeneity is reviewed in ref ⁵⁰). Whether the role of muscle ECs in trans-endothelial insulin transport (described further below) also reflects a tissue-specific EC characteristic remains to be determined. As such, EC heterogeneity is a given; its translation to differences in metabolic wiring, however, remains to be explored.

Metabolic features of ECs and accomplices in disease vessels

Given that ECs take the lead part but are not soloists in vascular disorders, the following section highlights the main metabolic changes in ECs in the disease state and looks for parallels and differences with or effects on the metabolism of other cell types involved, for as far as they have been studied. We focus on dysfunctional ECs in diabetes (Fig. 2A) and atherosclerosis (a frequent complication in diabetes) (Fig. 2B) and on excessively growing ECs in tumor blood vessels (Fig. 3A,B). Much like in healthy ECs, the data on EC metabolism in disease are mostly from *in vitro* / *ex vivo* experiments.

Diabetic ECs

Diabetics have increased blood glucose levels that drastically change EC metabolism and cause EC dysfunction. Hyperglycemia reduces G6PDH-mediated entry of glucose into the PPP, thereby lowering production of the main intracellular reductant NADPH and increasing oxidative stress levels ²¹. Contributing to this is the high glucose-induced activation of NADPH oxidases generating ROS ⁵¹. Excess glucose induces arginase activity, which consumes the NO-precursor arginine and as such uncouples the NO generating eNOS activity; instead superoxide anions are being produced. ROS together with reactive nitrogen species cause DNA strand breaks, which activate the enzyme polyADP-ribose polymerase (PARP1). The glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH; converting glyceraldehyde-3-phosphate (G3P) to 1,3-bisphosphoglycerate (1,3BPG)) is ADP-ribosylated by PARP1 (ref ⁵²), causing glycolytic flux to stall and glycolytic intermediates to pile up and to be diverted into the following ‘pathological’ pathways (Fig. 2A): 1) Excess glucose is shunted into the polyol pathway where it is converted to sorbitol by the rate-limiting enzyme aldose reductase (AR) ⁵³, a reaction that further depletes NADPH and increases ROS. Sorbitol in turn is converted to fructose by sorbitol dehydrogenase (SDH), which leads to the production of 3-deoxyglucosone (3DG), a highly reactive α -oxo-aldehyde that contributes to the non-enzymatic generation of toxic advanced glycation endproducts (AGE) ⁵⁴. 2) The fructose-6-phosphate (F6P) overload causes increased flux through the HBP, which, as discussed above, is crucial for protein glycosylation, but under hyperglycemic conditions impedes normal angiogenic behavior. eNOS activity, for example, is reduced by increased *O*-glycosylation ⁵⁵. 3) G3P and dihydroxyacetone phosphate (DHAP) are diverted towards methylglyoxal production, further contributing to ROS and AGE production. Also, G3P and DHAP are used for *de novo* synthesis of diacylglycerol (DAG) and subsequent protein kinase C (PKC) activation that has been shown to cause vascular abnormalities ⁵⁶. Remarkably, on top of stalling glycolysis and subsequently impacting glycolytic side-branches, hyperglycemia causes endothelial mitochondriopathy featuring defects in mitochondrial biogenesis and mitophagy (the latter causing damaged mitochondria to pile up), mitochondrial fragmentation and

impaired functionality and increased ROS production (reviewed in ref⁴⁸). Of note, GAPDH inactivation and glucose-shunting into glycolytic side-branches were remedied by normalizing mitochondrial ROS levels^{57, 58}.

As end products of dysfunctional EC metabolism, AGEs have far reaching effects on the ECs' immediate extracellular surroundings but also on other cells types. AGEs can crosslink key-molecules (eg, laminin, elastin, collagens) in the extracellular matrix (ECM) basement membrane causing increased vessel stiffness, which further contributes to the diabetes-related vascular complications (for more details the reader is referred to the following review⁵⁹). The broad intracellular effects of circulating AGEs are mediated through ligating the receptor for advanced glycation end products (RAGE), which is expressed in monocytes, smooth muscle cells (SMC) and ECs themselves⁶⁰. Contributing to vascular dysfunction, AGEs cause hyperpermeability and induce tissue factor expression leading to a more procoagulant endothelium⁵⁹. RAGE ligation in monocyte-derived macrophages increases the expression of macrophage scavenger receptor class A and CD36, favoring uptake of oxidized low-density lipoproteins (LDL)⁶¹. Conversely, efflux of cholesterol to high-density lipoprotein (HDL) is hampered by reduced expression of the ATP binding cassette transporter G1 in human macrophages exposed to AGE-bovine serum albumin; a finding that mainly depended on RAGE⁶². Both phenomena contribute to foam cell transformation, a key process in atherosclerosis (see below). In vascular smooth muscle cells (VSMCs), AGE-RAGE ligation increases proliferation and chemotactic migration, which contributes to VSMC accumulation in atherosclerotic plaques and is mediated by different signaling cascades (for more details the reader is referred to other reviews^{59, 60, 63}). In VSMCs, AGE-RAGE also induces autophagy via ERK/Akt signaling to metabolically sustain the increased proliferation⁶⁴, and induces inducible NOS (iNOS) activity through NADPH-oxidase derived ROS in an NF- κ B-dependent manner⁶⁵. In addition, AGEs in SMCs have been reported to cause increased fibronectin/ECM production and (vascular) calcification⁶⁶⁻⁶⁸.

The exact role for glutamine (metabolism) in diabetic endothelial cell dysfunction is not fully understood, although the effect of hyperglycemia on the HBP and subsequent eNOS inhibition (see above) proves the involvement of glutamine given that its γ -nitrogen is coupled to fructose-6-phosphate (F6P) to yield glucosamine-6-phosphate (GlucN6P) in the glutamine fructose-6-phosphate aminotransferase (GFAT)-mediated first and rate-limiting step of the HBP^{32, 69}. However, disease-mimicking high glucose treatment (25 mM) of the human umbilical vein endothelial cell line EA.hy926 revealed a small reduction in glutamine being oxidized⁷⁰. Interestingly, a genome-wide association study identified a single nucleotide polymorphism (SNP) on chromosome 1q25, which causes a 32% reduction in the expression of glutamine synthetase (GS or GLUL: the enzyme responsible for *de novo* glutamine synthesis) in ECs. Only in diabetic patients, and not in the non-diabetic participants, this SNP (occurring at an approximate allelic frequency of 0.7 in diabetics) leads to increased risk for coronary heart disease (CHD), with each risk allele carrying a 36% higher risk for CHD. Plasma pyroglutamic acid (an intermediate of the γ -glutamyl cycle and direct precursor for glutamic acid) to glutamic acid ratios were altered in diabetics homozygous for the SNP, but the exact causative mechanism remains to be determined⁷¹.

The available data on FAO in diabetic ECs appear highly contextual and somewhat contradictory. High glucose treatment of EA.hy926 ECs caused increased palmitate oxidation ⁷⁰, whereas a similar high glucose treatment on primary human umbilical vein ECs caused an increase in malonyl-coenzyme A levels (known to inhibit carnitine palmitoyltransferase-1 (CPT-1), the rate-limiting enzyme for FAO) and substantial decrease in FAO ⁷². Of note, leptin, of which the circulating levels are increased in diabetes, induces FAO in ECs by increasing CPT-1 activity and by lowering acetyl-CoA carboxylase (ACC; rate-limiting enzyme for fatty acid synthesis) activity ⁷³. Insulin resistance itself (under normal glucose levels/tolerance) increases FAO in aortic ECs ⁷⁴.

On a more systemic level, capillary blood flow in muscle is increased by insulin through increased eNOS expression and NO levels and subsequent vasodilation (capillary recruitment). This drives 'nutritive flow' and ensures transport across capillary ECs of glucose and insulin itself towards the muscle interstitium (for more details and possibly contradictory findings on insulin-induced capillary blood flow, the reader is referred to the following review ⁷⁵). Muscle (micro)-vascular dysfunction and reduced eNOS activity are among the earliest signs of insulin resistance and type 2 diabetes ⁷⁶.

Atherosclerosis

ECs in atherosclerosis display perturbations in metabolic pathways pertaining to NO generation. Atherosclerosis is characterized early on by uncoupled and reduced eNOS, resulting in an imbalance between the anti-atherogenic molecule NO and pro-atherogenic superoxides ⁷⁷. In the endothelium, eNOS normally generates NO through enzymatic oxidation of arginine to citrulline, requiring several cofactors including NADPH, flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), Ca²⁺/calmodulin and tetrahydrobiopterin (BH₄) ⁷⁸⁻⁸⁰. eNOS-derived NO mediates endothelium-dependent vasodilation, required for normal vascular homeostasis, and inhibits important events promoting atherosclerosis, such as platelet aggregation, smooth muscle cell proliferation and migration, leukocyte adhesion and oxidative stress ^{81, 82}. When the availability of the NO-precursor arginine and cofactor BH₄ is reduced, eNOS fails to produce NO and citrulline and instead produces ROS ^{77, 83}, a process called eNOS uncoupling (Fig. 2B).

The amino acid arginine is the main source for the generation of NO with approximately 1% of the daily arginine intake being metabolized through this pathway ⁸⁴. Even though endothelial and plasma levels of arginine are sufficiently high to support eNOS-dependent NO synthesis, arginine did appear to be rate-limiting in atherosclerotic patients with impaired endothelium-dependent vasodilation ⁸⁵. A possible explanation for this is the existence of endogenous arginine analogues such as asymmetric dimethyl arginine (ADMA) which antagonizes endothelium-dependent vasodilation and NO synthesis, by competing with arginine for binding to the catalytic center of eNOS ⁸⁶. ADMA plasma concentrations have been shown to be elevated up to 10-fold in atherosclerotic patients compared to healthy subjects and is now considered a major cardiovascular risk factor ⁸⁷. Approximately 80% of ADMA is eliminated through metabolization into citrulline and dimethylamine via dimethyl-arginine dimethyl-aminohydrolase (DDAH) ⁸⁸. DDAH is impaired by oxidative stress, allowing the accumulation of ADMA and subsequent inhibition of NO production ⁸⁹.

The remaining 20% of ADMA can also be metabolized by alanine-glyoxylate aminotransferase (AGXT2), a mitochondrial aminotransferase primarily expressed in the kidney. The competition between arginine and ADMA may explain why arginine supplementation is only beneficial in atherosclerotic patients with high ADMA plasma levels, and not in healthy patients with low ADMA plasma levels. Finally, oral supplementation of arginine not only benefits endothelium-dependent vasodilation, but was also shown to reverse the hyperadhesive phenotype of monocytes and T-lymphocytes in atherosclerotic patients ⁹⁰.

Next to eNOS uncoupling, NADPH oxidases are important sources of ROS in the vasculature ⁹¹. In early atherosclerotic vessels, endothelial-derived NADPH oxidases produce superoxides, whereas further along the disease, mainly VSMC-derived NADPH oxidases produce superoxides ^{92,93}. NADPH oxidases are induced in ECs and macrophages by plaque components such as oxidized LDL. Subsequent NADPH oxidase-derived ROS production has a detrimental effect in atherosclerosis by triggering increased expression of adhesion molecules, induction of VSMC proliferation and migration, apoptosis of ECs and oxidation of lipids. Much like hyperglycemia in diabetes (see above), atherosclerosis-inducing triglycerides and oxidized low-density lipoprotein (oxLDL) can cause endothelial mitochondria to become dysfunctional by damaging mitochondrial DNA and other vital components, eventually leading to increased ROS ⁴⁸.

The cofactor BH₄ is *de novo* produced from guanosine triphosphate (GTP) in the pathway where the highly regulated GTP cyclohydrolase I (GTPCH) is the first and rate-limiting enzyme. The endothelial cell-autonomous need for *de novo* BH₄ production was only recently confirmed in mice with EC-specific knock-out of GTPCH showing loss of EC NO activity and increased O₂^{•-} production ⁹⁴. Cellular BH₄ is oxidatively degraded to inactive 7,8-dihydrobiopterin (BH₂) and it is assumed that the intracellular BH₄/BH₂ ratio, rather than absolute BH₄ levels, is the key factor for eNOS uncoupling ⁹⁵. BH₄ is recovered through a salvage pathway in which dihydrofolate reductase (DHFR) reduces BH₂ back to BH₄ (ref ⁹⁶). The involvement of DHFR links BH₄ levels (and eNOS activity by extension) to one-carbon metabolism through which single carbon units from folates are transferred to methyl-acceptors (folate cycle) and in which methyltetrahydrofolate (mTHF) donates one-carbon to recycle methionine (and subsequently the methyl donor S-adenosylmethionine (SAM)) from homocysteine (methionine cycle) (for more details the reader is referred to the following review ⁹⁷) (Fig. 2B). Both homocysteine by itself (in *in vitro* assays) as well as inactivating mutations in methylenetetrahydrofolate reductase (MTHFR; the enzyme generating mTHF) leading to hyperhomocysteinemia lower BH₄ availability, possibly by affecting GTPCH and DHFR activity. Finally, recycling of the methyl donor SAM provides a link between one-carbon metabolism and ADMA (see above), which is generated through methylation of arginine residues by protein arginine N-methyltransferase (PRMT).

The EC mevalonate or isoprenoid pathways, which use acetyl-CoA to generate cholesterol, have a peculiar effect on eNOS transcript levels. Active RhoA/ROCK signaling, involved in regulating cell shape, polarity, contractility and locomotion by controlling cytoskeletal dynamics (see reviews ^{98,99}), reduces eNOS mRNA stability ¹⁰⁰. However, in order to be active and acquire its correct membranous localization, RhoA needs to be prenylated with

geranylgeranyl pyrophosphate (GGPP), an intermediate of the mevalonate pathway. The serum lipid lowering statins (see under translational opportunities below) inhibit the rate-limiting 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) in the mevalonate pathway and subsequently reduce cholesterol levels ¹⁰¹. A beneficial non-lipid lowering effect of statins, originating from the same inhibitory action, is to inhibit Rho activation in ECs by reducing the availability of geranylgeranyl and as such to restore eNOS expression levels ¹⁰². In contrast, by blocking the mevalonate pathway, statins also reduce the availability of farnesyl pyrophosphate, required for the synthesis of Coenzyme Q10, an important cofactor for eNOS ^{103, 104} (see also under Translational Opportunities). However, the effects on Rho prenylation are observed at statin doses far exceeding the clinically relevant dose, an important remark given the reported dose-dependency of statin effects on ECs (eg ref ¹⁰⁵). Noteworthy, regular-dose statins primarily affect Rac1 signaling by increasing the expression of the small GTP-binding protein GDP dissociation stimulator (SmgGDS), which causes nuclear translocation and subsequent degradation of Rac1 leading to reduced ROS levels ¹⁰⁶. For further reading on the pleiotropic effects of statins on ECs the reader is referred to the following reviews ^{107, 108}.

Furthermore, cholesterol metabolism drives the mischievous behavior of monocyte-derived macrophages in atherosclerosis. After ingestion by macrophages, lipoproteins' cholesteryl esters are converted into free cholesterol and fatty acids through hydrolysis in late endosomes ¹⁰⁹. Subsequently, the endoplasmic reticulum (ER) enzyme acyl-CoA:cholesterol acyltransferase (ACAT) converts free (unesterified) cholesterol into cholesteryl fatty acid esters through re-esterification; these cholesteryl fatty acid esters are the main component of foam cells ¹¹⁰. Incessant accumulation of free cholesterol may result in free cholesterol-induced cytotoxicity and subsequent inflammation and atherosclerotic lesion development. Cholesterol accumulation can be counteracted by ATP-binding cassette protein A1 (ABCA1) transporter-mediated cholesterol efflux to lipid-deficient apolipoprotein (Apo) A-I. Macrophages in ABCA1-deficient mice indeed have reduced cholesterol efflux ¹¹¹, while overexpression of ABCA1 in macrophages was associated with a substantial reduction in atherosclerosis ¹¹². A similar cholesterol efflux pathway to mature HDL exists via the scavenger receptor class B type I (SR-BI) or the ATP-binding cassette protein G1 (ABCG1) transporter ^{113, 114}; the expression of ABCG1 is reduced by AGEs produced by diabetic ECs (see above). Finally, apoA-I binding protein (AIBP)-mediated cholesterol efflux from ECs regulates proper EC function and proper VEGFR2-mediated angiogenesis, exemplified by the findings that knock-down or overexpression of *aibp* in zebrafish caused dysregulated and reduced angiogenesis, respectively ¹¹⁵.

Tumor vasculature

Within the tumor microenvironment, metabolic features of the cancer cells are mostly hardwired (driven by genetic alterations), whereas stromal cells adapt their normal metabolism to their environment and to meet the demands of the tumor. Even though full characterization of tumor EC metabolism is in its infancy, it most likely resembles the metabolism of highly activated ECs, since the tumor-induced switch from quiescence to proliferation and migration during sprouting is metabolically taxing. Normal, quiescent ECs display higher than expected glycolysis rates in order to generate sufficient energy to

maintain crucial functions (*eg* tight barrier function in certain vascular beds)^{3, 10, 116}; tumor ECs have increased lactate dehydrogenase B expression and probably further increase glycolysis as indicated by the induction of the glucose transporter GLUT1 in the tumor endothelium^{117, 118} and the capability of (tumor-derived) VEGF to induce PFKFB3 expression¹⁰ (Fig. 3A). In this respect, ECs and cancer cells are highly alike¹⁰ given that most cancer cells are highly glycolytic (Warburg effect¹¹⁹). Furthermore, both cell types co-compartmentalize glycolytic enzymes with actin-rich regions in invading structures such as filopodia (ECs) and invadopodia¹²⁰ (cancer cells) to ensure efficient energy production required for motility and invasion¹⁰.

Although the exact role of EC glutamine metabolism and the relative contribution of the two GLS isoforms (GLS1 vs GLS2) is undetermined, blocking GLS causes reduced EC proliferation and increased senescence³³, which suggests a crucial role for glutamine in tumor vessel sprouting, further supported by the notion that glutamine is the most abundant amino acid and a readily available carbon and nitrogen source. Cancer cells from their side have indeed rewired their glutamine metabolism to maximize glutamine carbon flux towards replenishment of the TCA cycle and nitrogen usage for nucleotide, amino acid and glutathione production. The *c-MYC* oncogene has been reported to underlie this rewiring by inducing glutaminolysis-related enzymes and rendering cancer cells 'glutamine-addicted'^{34, 35}. This dependency on glutamine is further exemplified by the recent findings that, under hypoxic conditions or impaired mitochondrial respiration, cancer cells can reductively carboxylate glutamine-derived α -ketoglutarate (α -KG) into citrate for *de novo* lipid synthesis^{121–123}. If and to what extent reductive carboxylation contributes to lipid synthesis in the predominantly glycolytic/hypoxic (see above) tumor ECs and total stromal compartment is currently an open question.

The glutamine-derived non-essential amino acid arginine is, as mentioned above, pivotal in EC behavior because of its precursor role in eNOS-mediated NO synthesis. Generation of the correct perivascular NO gradient by eNOS promotes vessel maturation¹²⁴. Cancer cells from their side express neuronal NOS (nNOS) or iNOS to generate NO, which perturbs the optimal perivascular NO gradient and renders tumor vessels abnormal^{124, 125}.

Ammonia, produced during the first two steps of glutaminolysis (deamination of glutamine to glutamate and glutamate to α -KG), is an auto- and paracrine inducer of autophagy¹²⁶. In co-culture systems, ammonia produced by high glutaminolysis rates in breast cancer cells, induced autophagy in cancer associated fibroblasts (CAFs) leading to increased proteolysis and increased glutamine levels, which in turn feeds the high glutaminolysis rate in the cancer cell compartment and as such closes the loop¹²⁷. *In vitro* glutamine deprivation causes osteosarcoma and lung cancer cells to excrete the pro-inflammatory chemokine interleukin-8 (IL-8), which has pro-angiogenic activity¹²⁸. An apparent ER stress and depletion of TCA intermediates underlies this phenomenon; treatment with dimethyl α -KG replenished the TCA and abrogated IL-8 excretion¹²⁹. Although the *in vivo* relevance of these findings remains to be determined, they exemplify how cancer cell metabolism instructs the stromal component (*cq* tumor ECs).

Much like ECs, fibroblasts maintain a relatively high glycolytic flux in quiescence to sustain basal cell functions and they approximately double this flux upon proliferation¹³⁰. CAFs have increased glycolysis rates to sustain a very peculiar relationship with cancer cells. The activity of oxygen-sensing prolyl-hydroxylase domain (PHD) proteins in CAFs is inhibited by high ROS levels coming from neighboring cancer cells. Subsequent hypoxia-inducible factor (HIF)-1 α stabilization causes excess NO production through autophagic degradation of caveolin-1, a repressor of NO production. These high NO levels cause mitochondria in CAFs to become dysfunctional and to be cleared through mitophagy; consequently, CAFs need to turn to glycolysis for energy production and as such supply lactate (and pyruvate) which cancer cells use to generate ATP in the TCA cycle^{131, 132}. This phenomenon contradicts the predominant view on cancer cells as the absolute “Warburgian” cells and has been coined the ‘Reverse Warburg effect’; the stromal compartment is suspected to be glycolytic (through mitochondrial dysfunction) and to feed energy-rich lactate into the TCA cycle of the cancer cell for highly efficient aerobic ATP production for anabolism and growth^{132, 133}. It remains to be determined if highly glycolytic tumor ECs engage in a similar host-parasite-like relationship with cancer cells as CAFs do (Fig. 3B).

Although the immune component of the tumor is intensively studied nowadays, insights to the metabolism of tumor-associated immune cells are lacking. Aerobic glycolysis is induced upon switching from a naive T cell to an activated T cell to fulfill the energy needs for proliferation, differentiation and activity (for more detailed information on the metabolic features of different T cell subtypes, we refer to other reviews^{12, 134}). If and how the move from the oxygen and nutrient-rich blood and lymph vessels to the harsh tumor microenvironment changes the metabolism of activated T cells is less well characterized. T cells in the tumor microenvironment display an ‘exhaustion’-like phenotype, a state of non-responsiveness and reduced effector function normally caused by constant antigen exposure (*cfr* chronic inflammation), and increase the expression of the immune-inhibitory programmed death receptor 1 (PD1) and the cytotoxic T-lymphocyte antigen-4 (CTLA4), ligation of which has been shown to reduce glycolysis^{135, 136}. Lactate excreted by cancer cells promotes IL-17A production, which negatively regulates T cell-mediated anti-tumor mechanisms¹³⁷. Although the metabolism of tumor associated macrophages (TAMs) is not fully known, these cells display a peculiarly divergent use of arginine within the tumor stroma depending on their polarization status (M1 *versus* M2 phenotype; see other reviews^{12, 138} for more detail). M1 macrophages suppress tumor growth and use arginine and iNOS to produce NO, which is toxic for cancer cells. Tumor growth promoting M2 macrophages use arginase 1 to convert arginine to ornithine which can feed proliferation of cancer cells¹³⁹.

Translational opportunities

The need for efficient and specific therapeutics to treat life-threatening vascular disorders is high. As evidenced above, diseased ECs reorient their core metabolism in dysfunction and during imbalanced angiogenesis raising the question if more ‘EC metabolism’-centric treatment strategies should be considered. Given that the necessary technical and conceptual advances to fully understand diseased EC metabolism to the tiniest details are starting to emerge only now, EC metabolism as a therapeutic target is still in its infancy. Nevertheless,

recent publications provided convincing proof of concept^{10, 13}. The current approach in tumor angiogenesis relies on blocking VEGF or its receptors; a ‘growth factor-centric’ treatment that suffers from tumor-based escape mechanisms (*ie* use of alternative additional growth factors to induce excess angiogenesis), leading to resistance¹⁴⁰. The recent data on how the glycolysis regulator PFKFB3 in ECs controls vessel sprouting in parallel to genetic signaling¹⁰ have generated seminal follow-up studies showing the advantage of (chemical) inhibition of PFKFB3 in treating pathological angiogenesis^{13, 141}. Noteworthy and probably of critical importance for future EC metabolism-centric approaches is the paradigm altering concept of partial and transient glycolysis reduction. The small molecule PFKFB3 inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) blocks EC glycolysis *in vivo* only transiently and by only 40% (corresponding to the difference in glycolysis rate between quiescent and proliferating/migrating ECs), sufficient to reduce pathological angiogenesis without affecting the healthy, quiescent vasculature¹³. Contrary to earlier belief, it is thus not necessary to block glycolysis permanently and completely – furthermore, this bears an increased risk for adverse effects.

Whether targeting PFKFB3 in ECs is a valuable strategy in atherosclerosis too is an unanswered question at present. *In vitro*, in response to the shear stress mimicking normal blood flow in mature vessels, the transcription factor KLF2 represses the expression of PFKFB3 to ensure the exact glycolytic flux required to maintain the ECs (phalanx cells) quiescent¹⁴. Given the high prevalence of atherosclerotic plaque formation at sites where disturbed flow impacts the ECs (*eg* bifurcations, the aortic lesser curvature) and possibly causes reduced KLF2 expression (reviewed in ref¹⁴²), it is tempting to speculate that ECs in these athero-prone regions have increased PFKFB3 levels and subsequently higher glycolysis rates; if so, partial glycolysis inhibition as described above might also prove valuable in atherosclerosis. In the context of atherosclerosis (or cardiovascular disorders by extension), serum lipid lowering treatments have proven to be highly beneficial. The HMG-CoA reductase blocking statins, for example, are among the most often prescribed drugs world-wide¹⁰¹. Interestingly, statins have additional beneficial effects such as inhibiting inflammatory processes but also a direct protective effect on the endothelium by increasing NO production (see above)¹⁴³. Even though they do mostly not outweigh the benefits, side effects such as myopathy, (possibly) increased diabetes incidence and statin intolerance, are linked to statin treatment¹⁰¹. Furthermore, by blocking HMG-CoA reductase in the mevalonate pathway, statins reduce the availability of farnesyl pyrophosphate, a precursor for Coenzyme Q10, an important antioxidant and co-factor for eNOS in ECs^{103, 104}. Therefore, in atherosclerosis too, additional/other EC-metabolism centric approaches, focused on normalizing eNOS activity, can be of future importance. The use of vascular-targeted nano-carriers which use EC-expressed inflammation markers as landing platform are a promising strategy to deliver possible drugs to the atherosclerotic lesion¹⁴⁴. Although challenging to accomplish, normalizing the pathologically increased or decreased flux through a given metabolic pathway will be key to successful novel treatments.

Acknowledgments

We would like to thank L. Notebaert for administrative assistance. We apologize to all colleagues whose work was not cited in this review due to space limitations and due to our attempt to cite the most recent literature.

Sources of funding

P.C. is supported by Federal Government Belgium grant (IUAP P7/03), long-term structural funding Methusalem funding by the Flemish Government, FWO grants, AXA Research Fund, ERC Advanced Research Grant and the Foundation Leducq Transatlantic Artemis Network. M.S. is supported in part by NIH grants HL053793, HL084619 and PO1 HL107205.

Non-standard abbreviations and acronyms

α-KG	α -ketoglutarate
(ox)LDL	(oxidized) low-density lipoprotein
(non-)oxPPP	(non-)oxidative pentose phosphate pathway
(V)SMC	(vascular) smooth muscle cell
1,3BPG	1,3-bisphosphoglycerate
3DG	3-deoxyglucosone
3PG	3-phosphoglycerate
3PO	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one
AA	amino acid
ABCA1	ATP-binding cassette protein A1
ABCG1	ATP-binding cassette protein G1
ACAT	acyl-CoA:cholesterol acyltransferase
ACC	acetyl-CoA carboxylase
acetyl-CoA	acetyl-coenzyme A
ADMA	asymmetric dimethyl arginine
AGE	advanced glycation end product
AGXT2	alanine-glyoxylate aminotransferase 2
AIBP	ApoA-I binding protein
AMPK	adenosine monophosphate activated protein kinase
Apo	apolipoprotein
AR	aldose reductase
ATP	adenosine triphosphate
BH₂	7,8-dihydrobiopterin
BH₄	tetrahydrobiopterin
CAF	cancer associated fibroblast
CD36	cluster of differentiation 36
CHD	coronary heart disease
CPT-1	carnitine palmitoyltransferase-1

CTLA4	cytotoxic T-lymphocyte antigen-4
DAG	diacylglycerol
DDAH	dimethyl-arginine dimethyl-aminohydrolase
DHAP	dihydroxyacetone phosphate
DHFR	dihydrofolate reductase
DII4	Delta like 4
EC	endothelial cell
ECM	extracellular matrix
eNOS	endothelial nitric oxide synthase
ER	endoplasmic reticulum
ERK	extracellular signal regulated kinase
ETC	electron transport chain
F1,6P₂	fructose-1,6-bisphosphate
F2,6P₂	fructose-2,6-bisphosphate
F6P	fructose-6-phosphate
FA(BP)	fatty acid (binding protein)
FAD	flavin adenine dinucleotide
FAO	fatty acid oxidation
FMN	flavin mononucleotide
G3P	glyceraldehyde-3-phosphate
G6P	glucose-6-phosphate
G6PDH	glucose-6-phosphate dehydrogenase
GAPDH	glyceraldehyde-3-phosphate dehydrogenase
GFAT	glutamine fructose-6-phosphate amidotransferase
GGPP	geranylgeranyl pyrophosphate
GLS	glutaminase
GlucN6P	glucosamine-6-phosphate
GLUT	glucose transporter
GS/GLUL	glutamine synthetase
GSH	reduced glutathione
GSSG	oxidized glutathione
GTP	guanosine triphosphate

GTPCH	GTP cyclohydrolase
HBP	hexosamine biosynthesis pathway
hCYS	homocysteine
HDL	high-density lipoprotein
HIF	hypoxia-inducible factor
HMG-CoA	hydroxymethylglutaryl coenzyme A
IL	interleukin
iNOS	inducible nitric oxide synthase
KLF2	Krüppel-like factor 2
LDH	lactate dehydrogenase
LPL	lipoprotein lipase
MET	methionine
mTHF	5-methyltetrahydrofolate
MTHFR	methylenetetrahydrofolate reductase
NADPH	nicotinamide adenine dinucleotide phosphate
NF-κB	nuclear factor κB
NICD	Notch intracellular domain
nNOS	neuronal nitric oxide synthetase
NO	nitric oxide
OAA	oxaloacetate
OXPHOS	oxidative phosphorylation
PARP1	polyADP-ribose polymerase 1
PD1	programmed death receptor 1
PDGF-B	platelet derived growth factor B
PDGF-Rβ	platelet derived growth factor receptor β
PFK1	phosphofructokinase-1
PFKFB3	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3
PHD	prolyl hydroxylase domain
PKC	protein kinase C
PRMT	protein arginine N-methyltransferase
R5P	ribose-5-phosphate
RAGE	receptor for advanced glycation end products

ROCK	Rho-associated protein kinase
ROS	reactive oxygen species
Ru5P	ribulose-5-phosphate
SAM	S-adenosylmethionine
SDH	sorbitol dehydrogenase
SLC1A5	solute carrier family 1 member 5
SmgGDS	small GTP-binding protein GDP dissociation stimulator
SNP	single nucleotide polymorphism
SR-B1	scavenger receptor class B type I
TAM	tumor associated macrophage
TCA	tricarboxylic acid
THF	tetrahydrofolate
UDP-glucNAc	uridine diphosphate N-acetylglucosamine
VEGF(R)	vascular endothelial growth factor (receptor)

References

1. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. *Nature*. 2011; 473:298–307. [PubMed: 21593862]
2. Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. *Cell*. 2010; 140:460–476. [PubMed: 20178740]
3. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. *Cell*. 2011; 146:873–887. [PubMed: 21925313]
4. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, Tian YM, Lanahan AA, Pollard P, Ruiz de Almodovar C, De Smet F, Vinckier S, Aragones J, Debackere K, Luttun A, Wyns S, Jordan B, Pisacane A, Gallez B, Lampugnani MG, Dejana E, Simons M, Ratcliffe P, Maxwell P, Carmeliet P. Heterozygous deficiency of phd2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. *Cell*. 2009; 136:839–851. [PubMed: 19217150]
5. Phng LK, Gerhardt H. Angiogenesis: A team effort coordinated by notch. *Developmental cell*. 2009; 16:196–208. [PubMed: 19217422]
6. Jakobsson L, Franco CA, Bentley K, Collins RT, Ponsioen B, Aspalter IM, Rosewell I, Busse M, Thurston G, Medvinsky A, Schulte-Merker S, Gerhardt H. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. *Nature Cell Biology*. 2010; 12:943–953.
7. Gaengel K, Genove G, Armulik A, Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. *Arteriosclerosis, thrombosis, and vascular biology*. 2009; 29:630–638.
8. Groschner LN, Waldeck-Weiermair M, Malli R, Graier WF. Endothelial mitochondria--less respiration, more integration. *Pflugers Archiv : European journal of physiology*. 2012; 464:63–76. [PubMed: 22382745]
9. Dagher Z, Ruderman N, Tornheim K, Ido Y. Acute regulation of fatty acid oxidation and amp-activated protein kinase in human umbilical vein endothelial cells. *Circulation research*. 2001; 88:1276–1282. [PubMed: 11420304]

10. De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR, Quaegebeur A, Ghesquiere B, Cauwenberghs S, Eelen G, Phng LK, Betz I, Tembuyser B, Brepoels K, Welti J, Geudens I, Segura I, Cruys B, Bifari F, Decimo I, Blanco R, Wyns S, Vangindertael J, Rocha S, Collins RT, Munck S, Daelemans D, Imamura H, Devlieger R, Rider M, Van Veldhoven PP, Schuit F, Bartrons R, Hofkens J, Fraisl P, Telang S, Deberardinis RJ, Schoonjans L, Vinckier S, Chesney J, Gerhardt H, Dewerchin M, Carmeliet P. Role of pfkfb3-driven glycolysis in vessel sprouting. *Cell*. 2013; 154:651–663. [PubMed: 23911327]
11. Mertens S, Noll T, Spahr R, Krutzfeldt A, Piper HM. Energetic response of coronary endothelial cells to hypoxia. *The American journal of physiology*. 1990; 258:H689–694. [PubMed: 2316683]
12. Ghesquiere B, Wong BW, Kuchnio A, Carmeliet P. Metabolism of stromal and immune cells in health and disease. *Nature*. 2014; 511:167–176. [PubMed: 25008522]
13. Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquiere B, Cauwenberghs S, Kuchnio A, Wong BW, Quaegebeur A, Goveia J, Bifari F, Wang X, Blanco R, Tembuyser B, Cornelissen I, Bouche A, Vinckier S, Diaz-Moralli S, Gerhardt H, Telang S, Cascante M, Chesney J, Dewerchin M, Carmeliet P. Partial and transient reduction of glycolysis by pfkfb3 blockade reduces pathological angiogenesis. *Cell metabolism*. 2014; 19:37–48. [PubMed: 24332967]
14. Doddaballapur A, Michalik KM, Manavski Y, Lucas T, Houtkooper RH, You X, Chen W, Zeiher AM, Potente M, Dimmeler S, Boon RA. Laminar shear stress inhibits endothelial cell metabolism via klf2-mediated repression of pfkfb3. *Arteriosclerosis, thrombosis, and vascular biology*. 2015; 35:137–145.
15. Slawson C, Copeland RJ, Hart GW. O-glcnaC signaling: A metabolic link between diabetes and cancer? *Trends in biochemical sciences*. 2010; 35:547–555. [PubMed: 20466550]
16. Benedito R, Roca C, Sorensen I, Adams S, Gossler A, Fruttiger M, Adams RH. The notch ligands *dll4* and *jagged1* have opposing effects on angiogenesis. *Cell*. 2009; 137:1124–1135. [PubMed: 19524514]
17. Vaisman N, Gospodarowicz D, Neufeld G. Characterization of the receptors for vascular endothelial growth factor. *The Journal of biological chemistry*. 1990; 265:19461–19466. [PubMed: 2246236]
18. Merchan JR, Kovacs K, Railsback JW, Kurtoglu M, Jing Y, Pina Y, Gao N, Murray TG, Lehrman MA, Lampidis TJ. Antiangiogenic activity of 2-deoxy-d-glucose. *PloS one*. 2010; 5:e13699. [PubMed: 21060881]
19. Riganti C, Gazzano E, Polimeni M, Aldieri E, Ghigo D. The pentose phosphate pathway: An antioxidant defense and a crossroad in tumor cell fate. *Free radical biology & medicine*. 2012; 53:421–436. [PubMed: 22580150]
20. Vizan P, Sanchez-Tena S, Alcarraz-Vizan G, Soler M, Messeguer R, Pujol MD, Lee WN, Cascante M. Characterization of the metabolic changes underlying growth factor angiogenic activation: Identification of new potential therapeutic targets. *Carcinogenesis*. 2009; 30:946–952. [PubMed: 19369582]
21. Zhang Z, Apse K, Pang J, Stanton RC. High glucose inhibits glucose-6-phosphate dehydrogenase via camp in aortic endothelial cells. *The Journal of biological chemistry*. 2000; 275:40042–40047. [PubMed: 11007790]
22. Elmasri H, Karaaslan C, Teper Y, Ghelfi E, Weng M, Ince TA, Kozakewich H, Bischoff J, Cataltepe S. Fatty acid binding protein 4 is a target of vegf and a regulator of cell proliferation in endothelial cells. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2009; 23:3865–3873. [PubMed: 19625659]
23. Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: Fatty acid oxidation in the limelight. *Nature reviews. Cancer*. 2013; 13:227–232.
24. Jeon SM, Chandel NS, Hay N. Ampk regulates nadph homeostasis to promote tumour cell survival during energy stress. *Nature*. 2012; 485:661–665. [PubMed: 22660331]
25. Iso T, Maeda K, Hanaoka H, Suga T, Goto K, Syamsunarno MR, Hishiki T, Nagahata Y, Matsui H, Arai M, Yamaguchi A, Abumrad NA, Sano M, Suematsu M, Endo K, Hotamisligil GS, Kurabayashi M. Capillary endothelial fatty acid binding proteins 4 and 5 play a critical role in fatty acid uptake in heart and skeletal muscle. *Arteriosclerosis, thrombosis, and vascular biology*. 2013; 33:2549–2557.

26. Hagberg CE, Falkevall A, Wang X, Larsson E, Huusko J, Nilsson I, van Meeteren LA, Samen E, Lu L, Vanwildemeersch M, Klar J, Genove G, Pietras K, Stone-Elander S, Claesson-Welsh L, Yla-Herttuala S, Lindahl P, Eriksson U. Vascular endothelial growth factor b controls endothelial fatty acid uptake. *Nature*. 2010; 464:917–921. [PubMed: 20228789]
27. Kivela R, Bry M, Robciuc MR, Rasanen M, Taavitsainen M, Silvola JM, Saraste A, Hulmi JJ, Anisimov A, Mayranpaa MI, Lindeman JH, Eklund L, Hellberg S, Hlushchuk R, Zhuang ZW, Simons M, Djonov V, Knuuti J, Mervaala E, Alitalo K. Vegf-b-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. *EMBO molecular medicine*. 2014; 6:307–321. [PubMed: 24448490]
28. Davies BS, Beigneux AP, Barnes RH 2nd, Tu Y, Gin P, Weinstein MM, Nobumori C, Nyren R, Goldberg I, Olivecrona G, Bensadoun A, Young SG, Fong LG. Gpihbp1 is responsible for the entry of lipoprotein lipase into capillaries. *Cell metabolism*. 2010; 12:42–52. [PubMed: 20620994]
29. Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C. The role of nitric oxide on endothelial function. *Current vascular pharmacology*. 2012; 10:4–18. [PubMed: 22112350]
30. DeBerardinis RJ, Cheng T. Q's next: The diverse functions of glutamine in metabolism, cell biology and cancer. *Oncogene*. 2010; 29:313–324. [PubMed: 19881548]
31. Lohmann R, Souba WW, Bode BP. Rat liver endothelial cell glutamine transporter and glutaminase expression contrast with parenchymal cells. *The American journal of physiology*. 1999; 276:G743–750. [PubMed: 10070052]
32. Wu G, Haynes TE, Yan W, Meininger CJ. Presence of glutamine:Fructose-6-phosphate amidotransferase for glucosamine-6-phosphate synthesis in endothelial cells: Effects of hyperglycaemia and glutamine. *Diabetologia*. 2001; 44:196–202. [PubMed: 11270676]
33. Unterluggauer H, Mazurek S, Lener B, Hutter E, Eigenbrodt E, Zwerschke W, Jansen-Durr P. Premature senescence of human endothelial cells induced by inhibition of glutaminase. *Biogerontology*. 2008; 9:247–259. [PubMed: 18317946]
34. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV. C-myc suppression of mir-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. *Nature*. 2009; 458:762–765. [PubMed: 19219026]
35. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. *Proceedings of the National Academy of Sciences of the United States of America*. 2008; 105:18782–18787. [PubMed: 19033189]
36. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107:7455–7460. [PubMed: 20378837]
37. Strasser GA, Kaminker JS, Tessier-Lavigne M. Microarray analysis of retinal endothelial tip cells identifies cxcr4 as a mediator of tip cell morphology and branching. *Blood*. 2010; 115:5102–5110. [PubMed: 20154215]
38. Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. *Trends in biochemical sciences*. 2014; 39:191–198. [PubMed: 24657017]
39. Mishra RC, Tripathy S, Desai KM, Quest D, Lu Y, Akhtar J, Gopalakrishnan V. Nitric oxide synthase inhibition promotes endothelium-dependent vasodilatation and the antihypertensive effect of l-serine. *Hypertension*. 2008; 51:791–796. [PubMed: 18212272]
40. Mishra RC, Tripathy S, Quest D, Desai KM, Akhtar J, Dattani ID, Gopalakrishnan V. L-serine lowers while glycine increases blood pressure in chronic l-name-treated and spontaneously hypertensive rats. *J Hypertens*. 2008; 26:2339–2348. [PubMed: 19062365]
41. Tibbetts AS, Appling DR. Compartmentalization of mammalian folate-mediated one-carbon metabolism. *Annual review of nutrition*. 2010; 30:57–81.
42. Fisslthaler B, Fleming I. Activation and signaling by the amp-activated protein kinase in endothelial cells. *Circulation research*. 2009; 105:114–127. [PubMed: 19608989]
43. Li J, McCullough LD. Effects of amp-activated protein kinase in cerebral ischemia. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2010; 30:480–492.

44. Eijkelenboom A, Burgering BM. Foxos: Signalling integrators for homeostasis maintenance. *Nature reviews. Molecular cell biology*. 2013; 14:83–97.
45. Mihaylova MM, Shaw RJ. The ampk signalling pathway coordinates cell growth, autophagy and metabolism. *Nature cell biology*. 2011; 13:1016–1023.
46. Pollizzi KN, Powell JD. Integrating canonical and metabolic signalling programmes in the regulation of t cell responses. *Nature reviews. Immunology*. 2014; 14:435–446.
47. Parra-Bonilla G, Alvarez DF, Al-Mehdi AB, Alexeyev M, Stevens T. Critical role for lactate dehydrogenase a in aerobic glycolysis that sustains pulmonary microvascular endothelial cell proliferation. *American journal of physiology. Lung cellular and molecular physiology*. 2010; 299:L513–522. [PubMed: 20675437]
48. Tang X, Luo YX, Chen HZ, Liu DP. Mitochondria, endothelial cell function, and vascular diseases. *Frontiers in physiology*. 2014; 5:175. [PubMed: 24834056]
49. Ohga N, Ishikawa S, Maishi N, Akiyama K, Hida Y, Kawamoto T, Sadamoto Y, Osawa T, Yamamoto K, Kondoh M, Ohmura H, Shinohara N, Nonomura K, Shindoh M, Hida K. Heterogeneity of tumor endothelial cells: Comparison between tumor endothelial cells isolated from high- and low-metastatic tumors. *The American journal of pathology*. 2012; 180:1294–1307. [PubMed: 22245217]
50. Aird WC. Endothelial cell heterogeneity. *Cold Spring Harbor perspectives in medicine*. 2012; 2:a006429. [PubMed: 22315715]
51. Drummond GR, Sobey CG. Endothelial nadph oxidases: Which nox to target in vascular disease? *Trends in endocrinology and metabolism: TEM*. 2014; 25:452–463. [PubMed: 25066192]
52. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M. Inhibition of gapdh activity by poly(adp-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. *J Clin Invest*. 2003; 112:1049–1057. [PubMed: 14523042]
53. Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: Attractive, elusive, and resilient. *Exp Diabetes Res*. 2007; 2007:61038. [PubMed: 18224243]
54. Wautier JL, Schmidt AM. Protein glycation: A firm link to endothelial cell dysfunction. *Circ Res*. 2004; 95:233–238. [PubMed: 15297385]
55. Federici M, Menghini R, Mauriello A, Hribal ML, Ferrelli F, Lauro D, Sbraccia P, Spagnoli LG, Sesti G, Lauro R. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by o-linked glycosylation modification of signaling proteins in human coronary endothelial cells. *Circulation*. 2002; 106:466–472. [PubMed: 12135947]
56. Das Evcimen N, King GL. The role of protein kinase c activation and the vascular complications of diabetes. *Pharmacological research : the official journal of the Italian Pharmacological Society*. 2007; 55:498–510. [PubMed: 17574431]
57. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature*. 2000; 404:787–790. [PubMed: 10783895]
58. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. *Diabetes*. 2005; 54:1615–1625. [PubMed: 15919781]
59. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: Sparking the development of diabetic vascular injury. *Circulation*. 2006; 114:597–605. [PubMed: 16894049]
60. Ott C, Jacobs K, Haucke E, Navarrete Santos A, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. *Redox biology*. 2014; 2:411–429. [PubMed: 24624331]
61. Boyle JJ. Macrophage activation in atherosclerosis: Pathogenesis and pharmacology of plaque rupture. *Current vascular pharmacology*. 2005; 3:63–68. [PubMed: 15638783]
62. Isoda K, Folco EJ, Shimizu K, Libby P. Age-bsa decreases abcg1 expression and reduces macrophage cholesterol efflux to hdl. *Atherosclerosis*. 2007; 192:298–304. [PubMed: 17005185]
63. Chuah YK, Basir R, Talib H, Tie TH, Nordin N. Receptor for advanced glycation end products and its involvement in inflammatory diseases. *International journal of inflammation*. 2013; 2013:403460. [PubMed: 24102034]

64. Hu P, Lai D, Lu P, Gao J, He H. Erk and akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells. *International journal of molecular medicine*. 2012; 29:613–618. [PubMed: 22293957]
65. San Martin A, Foncea R, Laurindo FR, Ebensperger R, Griendling KK, Leighton F. Nox1-based naph oxidase-derived superoxide is required for vsmc activation by advanced glycation end-products. *Free Radic Biol Med*. 2007; 42:1671–1679. [PubMed: 17462535]
66. Sakata N, Meng J, Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. *Journal of atherosclerosis and thrombosis*. 2000; 7:169–176. [PubMed: 11480459]
67. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through rage/p38 mapk. *J Vasc Res*. 2009; 46:572–580. [PubMed: 19571577]
68. Wang Y, Zhang ZY, Chen XQ, Wang X, Cao H, Liu SW. Advanced glycation end products promote human aortic smooth muscle cell calcification in vitro via activating nf-kappab and down-regulating igf1r expression. *Acta pharmacologica Sinica*. 2013; 34:480–486. [PubMed: 23416929]
69. Wu G, Haynes TE, Li H, Yan W, Meiningner CJ. Glutamine metabolism to glucosamine is necessary for glutamine inhibition of endothelial nitric oxide synthesis. *The Biochemical journal*. 2001; 353:245–252. [PubMed: 11139387]
70. Koziel A, Woyda-Ploszczyca A, Kicinska A, Jarmuszkiewicz W. The influence of high glucose on the aerobic metabolism of endothelial ea.Hy926 cells. *Pflugers Archiv : European journal of physiology*. 2012; 464:657–669. [PubMed: 23053476]
71. Qi L, Qi Q, Prudente S, Mendonca C, Andreozzi F, di Pietro N, Sturma M, Novelli V, Mannino GC, Formoso G, Gervino EV, Hauser TH, Muehlschlegel JD, Niewczas MA, Krolewski AS, Biolo G, Pandolfi A, Rimm E, Sesti G, Trischitta V, Hu F, Doria A. Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes. *JAMA*. 2013; 310:821–828. [PubMed: 23982368]
72. Ido Y, Carling D, Ruderman N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: Inhibition by the amp-activated protein kinase activation. *Diabetes*. 2002; 51:159–167. [PubMed: 11756336]
73. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase a. *The Journal of biological chemistry*. 2001; 276:25096–25100. [PubMed: 11342529]
74. Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and enos activities by increasing endothelial fatty acid oxidation. *The Journal of clinical investigation*. 2006; 116:1071–1080. [PubMed: 16528409]
75. Richards OC, Raines SM, Attie AD. The role of blood vessels, endothelial cells, and vascular pericytes in insulin secretion and peripheral insulin action. *Endocrine reviews*. 2010; 31:343–363. [PubMed: 20164242]
76. Lesniewski LA, Donato AJ, Behnke BJ, Woodman CR, Laughlin MH, Ray CA, Delp MD. Decreased no signaling leads to enhanced vasoconstrictor responsiveness in skeletal muscle arterioles of the zdf rat prior to overt diabetes and hypertension. *American journal of physiology. Heart and circulatory physiology*. 2008; 294:H1840–1850. [PubMed: 18245568]
77. Kawashima S. Malfunction of vascular control in life-style related diseases: Endothelial nitric oxide (no) synthase/no system in atherosclerosis. *Journal of Pharmacology Science*. 2004; 96:411–419.
78. Moncada S, Higgs EA, Hodson HF, Knowles RG, Lopez-Jaramillo P, McCall T, Palmer RM, Radomski MW, Rees DD, Schulz R. The l-arginine:Nitric oxide pathway. *Journal of Cardiovascular Pharmacology*. 1991; 17:1–9. [PubMed: 1708041]
79. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. *Pharmacol Rev*. 1991; 43:109–142. [PubMed: 1852778]
80. Nathan C, Xie Q. Nitric oxide synthases: Roles, tolls, and controls. *Cell*. 1994; 78:915–918. [PubMed: 7522969]

81. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. *Circulation*. 2004; 109:27–32.
82. Kopincova J, Puzserova A, Bernatova I. L-name in the cardiovascular system - nitric oxide synthase activator? *Pharmacological Reports*. 2012; 64:511–520. [PubMed: 22814004]
83. Stroes E, Hijmering M, van Zandvoort M, Wever R, Rabelink TJ, van Faassen EE. Origin of superoxide production by endothelial nitric oxide synthase. *FEBS Letters*. 1998; 438:161–164. [PubMed: 9827538]
84. Castillo L, Chapman TE, Sanchez M, Yu Y, Burke JF, Ajami AM, Vogt J, Young VR. Plasma arginine and citrulline kinetics in adults given adequate and arginine-free diets. *PNAS*. 1993; 90:7749–7753. [PubMed: 8356080]
85. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (adma): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. *Circulation*. 1998; 98:1842–1847. [PubMed: 9799202]
86. Cooke JP. Does adma cause endothelial dysfunction? *Arterioscler Thromb Vasc Biol*. 2000; 20:2032–2037. [PubMed: 10978245]
87. Boger RH. Asymmetric dimethylarginine: Understanding the physiology, genetics, and clinical relevance of this novel biomarker. *Proceedings of the 4th international symposium on adma. Pharmacol Res*. 2009; 60:447. [PubMed: 19853807]
88. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. *Biochem J*. 1999; 343(Pt 1):209–214. [PubMed: 10493931]
89. Wilcox CS. Asymmetric dimethylarginine and reactive oxygen species: Unwelcome twin visitors to the cardiovascular and kidney disease tables. *Hypertension*. 2012; 59:375–381. [PubMed: 22215715]
90. Chan JR, Boger RH, Bode-Boger SM, Tangphao O, Tsao PS, Blaschke TF, Cooke JP. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. *Arterioscler Thromb Vasc Biol*. 2000; 20:1040–1046. [PubMed: 10764670]
91. Griendling KK, Sorescu D, Ushio-Fukai M. Nad(p)h oxidase: Role in cardiovascular biology and disease. *Circ Res*. 2000; 86:494–501. [PubMed: 10720409]
92. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. *Arteriosclerosis, thrombosis, and vascular biology*. 2004; 24:998–1005.
93. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Bohm M, Meinertz T, Munzel T. Increased nadh-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system. *Circulation*. 1999; 99:2027–2033. [PubMed: 10209008]
94. Chuaiphichai S, McNeill E, Douglas G, Crabtree MJ, Bendall JK, Hale AB, Alp NJ, Channon KM. Cell-autonomous role of endothelial gtp cyclohydrolase 1 and tetrahydrobiopterin in blood pressure regulation. *Hypertension*. 2014; 64:530–540. [PubMed: 24777984]
95. Crabtree MJ, Smith CL, Lam G, Goligorsky MS, Gross SS. Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in no vs. Superoxide production by enos. *Am J Physiol Heart Circ Physiol*. 2008; 294:H1530–1540. [PubMed: 18192221]
96. Bendall JK, Douglas G, McNeill E, Channon KM, Crabtree MJ. Tetrahydrobiopterin in cardiovascular health and disease. *Antioxidants & redox signaling*. 2014; 20:3040–3077. [PubMed: 24294830]
97. Locasale JW. Serine, glycine and one-carbon units: Cancer metabolism in full circle. *Nature reviews. Cancer*. 2013; 13:572–583.
98. Jaffe AB, Hall A. Rho gtpases: Biochemistry and biology. *Annual review of cell and developmental biology*. 2005; 21:247–269.
99. Riento K, Ridley AJ. Rocks: Multifunctional kinases in cell behaviour. *Nature reviews. Molecular cell biology*. 2003; 4:446–456.

100. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by rho GTPase. *The Journal of biological chemistry*. 1998; 273:24266–24271. [PubMed: 9727051]
101. Wilkinson MJ, Laffin LJ, Davidson MH. Overcoming toxicity and side-effects of lipid-lowering therapies. *Best practice & research. Clinical endocrinology & metabolism*. 2014; 28:439–452. [PubMed: 24840269]
102. Rolfe BE, Worth NF, World CJ, Campbell JH, Campbell GR. Rho and vascular disease. *Atherosclerosis*. 2005; 183:1–16. [PubMed: 15982657]
103. Mugoni V, Postel R, Catanzaro V, De Luca E, Turco E, Digilio G, Silengo L, Murphy MP, Medana C, Stainer DY, Bakkers J, Santoro MM. Ubiad1 is an antioxidant enzyme that regulates eNOS activity by coq10 synthesis. *Cell*. 2013; 152:504–518. [PubMed: 23374346]
104. Tsai KL, Huang YH, Kao CL, Yang DM, Lee HC, Chou HY, Chen YC, Chiou GY, Chen LH, Yang YP, Chiu TH, Tsai CS, Ou HC, Chiou SH. A novel mechanism of coenzyme Q10 protects against human endothelial cells from oxidative stress-induced injury by modulating NO-related pathways. *The Journal of nutritional biochemistry*. 2012; 23:458–468. [PubMed: 21684136]
105. Urbich C, Dernbach E, Zeiher AM, Dimmeler S. Double-edged role of statins in angiogenesis signaling. *Circulation research*. 2002; 90:737–744. [PubMed: 11934843]
106. Tanaka S, Fukumoto Y, Nochioka K, Minami T, Kudo S, Shiba N, Takai Y, Williams CL, Liao JK, Shimokawa H. Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. *Arteriosclerosis, thrombosis, and vascular biology*. 2013; 33:1591–1600.
107. Jacobson JR. Statins in endothelial signaling and activation. *Antioxidants & redox signaling*. 2009; 11:811–821. [PubMed: 18808324]
108. Margaritis M, Channon KM, Antoniades C. Statins as regulators of redox state in the vascular endothelium: Beyond lipid lowering. *Antioxidants & redox signaling*. 2014; 20:1198–1215. [PubMed: 24111702]
109. Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. *Nature*. 2005; 438:612–621. [PubMed: 16319881]
110. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. *Cell*. 2011; 145:341–355. [PubMed: 21529710]
111. Haghpassand M, Bourassa PA, Francone OL, Aiello RJ. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. *J Clin Invest*. 2001; 108:1315–1320. [PubMed: 11696576]
112. Van Eck M, Singaraja RR, Ye D, Hildebrand RB, James ER, Hayden MR, Van Berkel TJ. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. *Arteriosclerosis, thrombosis, and vascular biology*. 2006; 26:929–934.
113. Trigatti B, Rayburn H, Vinals M, Braun A, Miettinen H, Penman M, Hertz M, Schrenzel M, Amigo L, Rigotti A, Krieger M. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. *Proc Natl Acad Sci U S A*. 1999; 96:9322–9327. [PubMed: 10430941]
114. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters ABCA1 and ABCA2 mediate cellular cholesterol efflux to high-density lipoproteins. *Proc Natl Acad Sci U S A*. 2004; 101:9774–9779. [PubMed: 15210959]
115. Fang L, Choi SH, Baek JS, Liu C, Almazan F, Ulrich F, Wiesner P, Taleb A, Deer E, Pattison J, Torres-Vazquez J, Li AC, Miller YI. Control of angiogenesis by ABCA1-mediated cholesterol efflux. *Nature*. 2013; 498:118–122. [PubMed: 23719382]
116. Curry FE, Adamson RH. Endothelial glycocalyx: Permeability barrier and mechanosensor. *Annals of biomedical engineering*. 2012; 40:828–839. [PubMed: 22009311]
117. van Beijnum JR, Dings RP, van der Linden E, Zwaans BM, Ramaekers FC, Mayo KH, Griffioen AW. Gene expression of tumor angiogenesis dissected: Specific targeting of colon cancer angiogenic vasculature. *Blood*. 2006; 108:2339–2348. [PubMed: 16794251]

118. Yeh WL, Lin CJ, Fu WM. Enhancement of glucose transporter expression of brain endothelial cells by vascular endothelial growth factor derived from glioma exposed to hypoxia. *Molecular pharmacology*. 2008; 73:170–177. [PubMed: 17942749]
119. Ferreira LM. Cancer metabolism: The warburg effect today. *Experimental and molecular pathology*. 2010; 89:372–380. [PubMed: 20804748]
120. van Horssen R, Buccione R, Willemsse M, Cingir S, Wieringa B, Attanasio F. Cancer cell metabolism regulates extracellular matrix degradation by invadopodia. *European journal of cell biology*. 2013; 92:113–121. [PubMed: 23306026]
121. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, Kelleher JK, Vander Heiden MG, Iliopoulos O, Stephanopoulos G. Reductive glutamine metabolism by *idh1* mediates lipogenesis under hypoxia. *Nature*. 2012; 481:380–384. [PubMed: 22101433]
122. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS, DeBerardinis RJ. Reductive carboxylation supports growth in tumour cells with defective mitochondria. *Nature*. 2012; 481:385–388. [PubMed: 22101431]
123. Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, Platt JM, DeMatteo RG, Simon MC, Thompson CB. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. *Proc Natl Acad Sci U S A*. 2011; 108:19611–19616. [PubMed: 22106302]
124. Kashiwagi S, Tsukada K, Xu L, Miyazaki J, Kozin SV, Tyrrell JA, Sessa WC, Gerweck LE, Jain RK, Fukumura D. Perivascular nitric oxide gradients normalize tumor vasculature. *Nature medicine*. 2008; 14:255–257.
125. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. *Nature reviews. Drug discovery*. 2011; 10:417–427.
126. Eng CH, Yu K, Lucas J, White E, Abraham RT. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. *Science signaling*. 2010; 3:ra31. [PubMed: 20424262]
127. Ko YH, Lin Z, Flomenberg N, Pestell RG, Howell A, Sotgia F, Lisanti MP, Martinez-Outschoorn UE. Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: Implications for preventing chemotherapy resistance. *Cancer biology & therapy*. 2011; 12:1085–1097. [PubMed: 22236876]
128. Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter *mct1* supports an *nf-kappab/il-8* pathway that drives tumor angiogenesis. *Cancer research*. 2011; 71:2550–2560. [PubMed: 21300765]
129. Shanware NP, Bray K, Eng CH, Wang F, Follettie M, Myers J, Fantin VR, Abraham RT. Glutamine deprivation stimulates *mtor-jnk*-dependent chemokine secretion. *Nature communications*. 2014; 5:4900.
130. Lemons JM, Feng XJ, Bennett BD, Legesse-Miller A, Johnson EL, Raitman I, Pollina EA, Rabitz HA, Rabinowitz JD, Collier HA. Quiescent fibroblasts exhibit high metabolic activity. *PLoS biology*. 2010; 8:e1000514. [PubMed: 21049082]
131. Pavlides S, Vera I, Gandara R, Sneddon S, Pestell RG, Mercier I, Martinez-Outschoorn UE, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP. Warburg meets autophagy: Cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. *Antioxidants & redox signaling*. 2012; 16:1264–1284. [PubMed: 21883043]
132. Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, Pavlides S, Whitaker-Menezes D, Tsigos A, Witkiewicz A, Lin Z, Balliet R, Howell A, Sotgia F. Understanding the “lethal” drivers of tumor-stroma co-evolution: Emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. *Cancer biology & therapy*. 2010; 10:537–542. [PubMed: 20861671]
133. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. The reverse warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. *Cell cycle*. 2009; 8:3984–4001. [PubMed: 19923890]

134. Mockler MB, Conroy MJ, Lysaght J. Targeting t cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment. *Frontiers in oncology*. 2014; 4:107. [PubMed: 24904823]
135. Schietinger A, Greenberg PD. Tolerance and exhaustion: Defining mechanisms of t cell dysfunction. *Trends in immunology*. 2014; 35:51–60. [PubMed: 24210163]
136. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL. Ctlα-4 and pd-1 receptors inhibit t-cell activation by distinct mechanisms. *Molecular and cellular biology*. 2005; 25:9543–9553. [PubMed: 16227604]
137. Yabu M, Shime H, Hara H, Saito T, Matsumoto M, Seya T, Akazawa T, Inoue N. Il-23-dependent and -independent enhancement pathways of il-17a production by lactic acid. *International immunology*. 2011; 23:29–41. [PubMed: 21131367]
138. Galvan-Pena S, O'Neill LA. Metabolic reprogramming in macrophage polarization. *Frontiers in immunology*. 2014; 5:420. [PubMed: 25228902]
139. Mills CD. M1 and m2 macrophages: Oracles of health and disease. *Critical reviews in immunology*. 2012; 32:463–488. [PubMed: 23428224]
140. Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. *The Journal of clinical investigation*. 2013; 123:3190–3200. [PubMed: 23908119]
141. Xu Y, An X, Guo X, Habtetsion TG, Wang Y, Xu X, Kandala S, Li Q, Li H, Zhang C, Caldwell RB, Fulton DJ, Su Y, Hoda MN, Zhou G, Wu C, Huo Y. Endothelial pfkfb3 plays a critical role in angiogenesis. *Arteriosclerosis, thrombosis, and vascular biology*. 2014; 34:1231–1239.
142. Davies PF, Civelek M, Fang Y, Fleming I. The atherosusceptible endothelium: Endothelial phenotypes in complex haemodynamic shear stress regions in vivo. *Cardiovascular research*. 2013; 99:315–327. [PubMed: 23619421]
143. Biasucci LM, Biasillo G, Stefanelli A. Inflammatory markers, cholesterol and statins: Pathophysiological role and clinical importance. *Clinical chemistry and laboratory medicine : CCLM / FESCC*. 2010; 48:1685–1691. [PubMed: 20868311]
144. Lobatto ME, Fuster V, Fayad ZA, Mulder WJ. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. *Nature reviews. Drug discovery*. 2011; 10:835–852.




Figure 1. General metabolism in healthy ECs

Schematic and simplified overview of general EC metabolism. Abbreviations used: 3PG: 3-phosphoglycerate; α-KG: α-ketoglutarate; ATP: adenosine triphosphate; DHAP: dihydroxyacetone phosphate; ETC: electron transport chain; Fu1,6P₂: fructose-1,6-bisphosphate; F2,6P₂: fructose-2,6-bisphosphate; F6P: fructose-6-phosphate; FA: fatty acid; G3P: glyceraldehyde-3-phosphate; G6P: glucose-6-phosphate; GLS: glutaminase; GlucN6P: glucosamine-6-phosphate; hCYS: homocysteine; mTHF: 5-methyltetrahydrofolate; NADPH: nicotinamide adenine dinucleotide phosphate; NO: nitric oxide; OAA: oxaloacetate; PFK1: phosphofructokinase-1; PFKFB3: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3; R5P: ribose-5-phosphate; ROS: reactive oxygen species; Ru5P: ribulose-5-phosphate; SAM: S-adenosylmethionine; SLC1A5: solute carrier family 1 member 5; THF: tetrahydrofolate; UDP-GlucNAc: uridine diphosphate N-acetylglucosamine.




Figure 2. Metabolic pathways involved in disease characterized by EC dysfunction

A, In diabetes, hyperglycemia triggers mainly increased ROS production through eNOS uncoupling and PPP impairment resulting in stalled glycolytic flux with glycolytic intermediates being diverted into alternative metabolic pathways leading to additional excess ROS and AGEs production. **B**, Atherosclerosis is characterized at a metabolic level mainly by eNOS uncoupling resulting in excess ROS production and loss of NO-dependent vasodilation. Abbreviations used: as in Figure 1. 1,3BPG: 1,3-bisphosphoglycerate; 3DG: 3-deoxyglucosone; ADMA: asymmetric dimethyl arginine; AGE: advanced glycation end product; AGXT2: alanine-glyoxylate aminotransferase; AR: aldose reductase; BH₂: 7,8-dihydrobiopterin; BH₄: tetrahydrobiopterin; DAG: diacylglycerol; DDAH: dimethyl-arginine dimethyl-aminohydrolase; DHFR: dihydrofolate reductase; eNOS: endothelial nitric oxide synthase; G6PDH: glucose-6-phosphate dehydrogenase; GADPH: glyceraldehyde-3-phosphate dehydrogenase; GFAT: glutamine fructose-6-phosphate

amidotransferase; GGPP: geranylgeranyl pyrophosphate; GTP: guanosine triphosphate; GTPCH: GTP cyclohydrolase; HMG-CoA: hydroxymethylglutaryl coenzyme A; HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase; MET: methionine; MTHFR: methylenetetrahydrofolate reductase; PARP1: polyADP-ribose polymerase 1; PKC: protein kinase C; PPP: pentose phosphate pathway; SDH: sorbitol dehydrogenase.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 3. Metabolic pathways in tumor vessels and metabolic interactions between cancer and stromal cells

A, ECs in tumor vasculature are presumably characterized by increased glycolysis. **B**, Metabolic interactions between cancer and stromal cells. Abbreviations used: as in Figures 1 and 2. ER: endoplasmic reticulum; GLUT: glucose transporter; HIF: hypoxia-inducible factor; IL-8: interleukin-8; LDH: lactate dehydrogenase; PHD: prolyl hydroxylase domain.